Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

被引:227
作者
Sridhar, SS
Seymour, L
Shepherd, FA
机构
[1] Princess Margaret Hosp, Univ Hlth Network, Dept Med, Div Med Oncol, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Natl Canc Inst, Canada Clin Trials Grp, Investigat New Drug Program, Kingston, ON, Canada
[4] Queens Univ, Kingston, ON K7L 3N6, Canada
关键词
D O I
10.1016/S1470-2045(03)01137-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite aggressive surgical and chemotherapeutic interventions, non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death in men and women with overall cure rates of less than 15%. Recent advances in our understanding of cellular signalling and its critical role in tumorigenesis has led to the development of novel therapies which may offer new hope. In particular, the epidermal growth-factor receptor superfamily is an attractive therapeutic target because it is commonly overexpressed in malignant disease, regulates many vital cellular processes, and seems to be a negative prognostic indicator. Several selective inhibitors of this family of receptors are currently being evaluated in several cancers including NSCLC. In this review we examine current preclinical and clinical evidence on monoclonal antibodies (cetuximab, ABX-EGF, EMD72000, MAb ICR62, h-R3, MDX-447, MDX-H210, trastuzumab, and 2C4), immunoconjugates (Y10, Ua30:2, Mab806), anti-EGF vaccine (YMB2000), and tyrosine kinase inhibitors (gefitinib, erlotinib, CI1033, GW572016, EKB 569, PKI166, PD158780, and TAK 165).
引用
收藏
页码:397 / 406
页数:10
相关论文
共 77 条
[41]  
JOHNSON DH, 2002, ANN ONCOL, V13, P127
[42]  
KELLY K, 2003, P AN M AM SOC CLIN, V22, P644
[43]  
KIM ES, 2003, P AN M AM SOC CLIN, V22, P642
[44]  
KRIS MG, 2002, P AN M AM SOC CLIN, V21, P2929
[45]   Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment [J].
Lynch, DH ;
Yang, XD .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :47-50
[46]   Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer [J].
Modjtahedi, H ;
Hickish, T ;
Nicolson, M ;
Moore, J ;
Styles, J ;
Eccles, S ;
Jackson, E ;
Salter, J ;
Sloane, J ;
Spencer, L ;
Priest, K ;
Smith, I ;
Dean, C ;
Gore, M .
BRITISH JOURNAL OF CANCER, 1996, 73 (02) :228-235
[47]   Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma [J].
Morales-Morales, A ;
Ducongé, J ;
Caballero-Torres, I ;
Núñez-Gandolff, G ;
Fernández, E ;
Iznaga-Escobar, N .
NUCLEAR MEDICINE AND BIOLOGY, 1999, 26 (03) :275-279
[48]   Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody [J].
Needle, MN .
SEMINARS IN ONCOLOGY, 2002, 29 (05) :55-60
[49]  
NESBITT JC, 1997, CANC MED, P1723
[50]   A new antibody recognizing the vIII mutation of human epidermal growth factor receptor [J].
Öhman, L ;
Gedda, L ;
Hesselager, G ;
Larsson, R ;
Nister, M ;
Stigbrand, T ;
Wester, K ;
Carlsson, J .
TUMOR BIOLOGY, 2002, 23 (02) :61-69